Payer PolicyActive
CMM-204: Prolotherapy
EVICORE-MSK_ADVANCED-E777ECFF
EviCore by Evernorth
Effective: May 31, 2023
Updated: January 13, 2026
created · Dec 5, 2025
Policy Summary
Prolotherapy (CPT M0076) for musculoskeletal pain or instability is considered experimental, investigational, or unproven and is excluded from coverage. Evidence is inconclusive, the treatment may cause serious side effects, reimbursement is determined by the individual’s health plan (atypical cases require physician review/consultation) and no specific documentation or prerequisites are specified.
Coverage Criteria Preview
Key requirements from the full policy
"Prolotherapy performed for the treatment of musculoskeletal pain and/or instability (e."
Sign up to see full coverage criteria, indications, and limitations.